| Literature DB >> 29340759 |
Kana Matsuda1, Shoko Ono2, Marin Ishikawa1, Shuichi Miyamoto1, Satoshi Abiko1, Momoko Tsuda1, Keiko Yamamoto3, Takahiko Kudo1, Yuichi Shimizu3, Eiko Hayase4, Daigo Hashimoto4, Takanori Teshima4, Yoshihiro Matsuno5, Naoya Sakamoto1.
Abstract
Although graft-versus-host disease (GVHD) is the major complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT), cytomegalovirus (CMV) reactivation also occurs in patients after allo-HSCT and these conditions often clinically overlap. The aim of this study was to determine reliable endoscopic findings of CMV colitis in patients with gastrointestinal graft-versus-host-disease (GI-GVHD). Patients after allo-HSCT who were histologically confirmed to have GI-GVHD with or without CMV colitis and patients with an immunosuppressive condition were retrospectively analyzed. We divided the patients into three groups: GI-GVHD with CMV colitis (group A), GI-GVHD without CMV colitis (group B), and CMV colitis without undergoing allo-HSCT (group C). From medical records, the involved colorectal areas and endoscopic findings according to the groups were compared. A total of 70 patients were divided into three groups (group A: n = 19, group B: n = 28, group C: n = 23). Mucosal injuries in groups A and C frequently occurred in the cecum including ileocecal valves. On the other hand, there were no abnormal lesions on ileocecal valves in group B. Furthermore, ulcer lesions were more frequently observed in groups A and C than in group B (p < 0.001). The sensitivity and specificity of mucosal injuries in the cecum for prediction of CMV colitis were 89.5 and 76.5%, respectively, and mucosal injuries in the cecum were more reliable findings than CMV antigenemia. Ulcer lesions in the cecum are reliable endoscopic findings for CMV colitis in patients with GI-GVHD after allo-HSCT.Entities:
Keywords: CMV; Cytomegalovirus; GVHD; Graft-versus-host-disease; Infection
Mesh:
Year: 2018 PMID: 29340759 DOI: 10.1007/s00277-018-3241-9
Source DB: PubMed Journal: Ann Hematol ISSN: 0939-5555 Impact factor: 3.673